Skip to main content

Contact Information

Bruce ConwayBruce Conway, Ph.D.
Program Director, Robertson Therapeutic Development Fund

Dr. Bruce Conway came to Rockefeller in 2014 as the Founding Director of the Robertson Therapeutic Development Fund (RTDF). In this role, Bruce works with Rockefeller researchers to provide mentorship and guide the design and execution of RTDF projects, keeping value creation and clinical goals in mind. He also oversees projects supported by the university’s new Kellen Women’s Entrepreneurship Fund.

Bruce previously served as an “Executive-in-Residence” at Columbia University, where he worked with academic researchers to provide mentoring and guidance for development-stage activities for therapeutics, diagnostics, and medical devices.

Prior to moving to academia, Bruce was the Senior Director of Biology at the Institutes for Pharmaceutical Discovery, where he oversaw the day-to-day operations of the Biology, Pharmacology, and Drug Metabolism and Pharmacokinetics teams. During this time, he and several colleagues leveraged assets from Yale University to launch OncoArendi Therapeutics—a company focused on the development of novel therapies for inflammatory disease and cancer.

Dr. Conway began his career in the pharmaceutical industry at Johnson & Johnson Pharmaceutical Research and Development, where he led multiple drug discovery projects and championed the progression of three compounds toward the clinic, one of which resulted in the FDA approval of a novel, first-in-class treatment for type 2 diabetes, Invokana®.

Bruce earned his Ph.D. in Pharmacology at the Medical College of Virginia and completed a postdoctoral fellowship at the University of Massachusetts Medical Center. Bruce is an inventor on 10 issued patents and has co-authored more than 30 original publications, as well as several reviews and book chapters.